GSK Investigational Site

Des Moines, Iowa 50314

0 studies enrolling now · 22 studies all time

What they study most

Anaemia, Asthma, Diabetes Mellitus, Type 2, Dyskinesias, Epilepsy, Epilepsy, Partial, Epilepsy, Tonic-Clonic, HIV Infection, Haemophilus Influenzae Type b, Infection, Human Immunodeficiency Virus I, Infections, Meningococcal, Metastatic Breast Cancer

Studies at this site

• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) — Completed
• Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 — Completed
• Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine — Completed
• Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine — Completed
• Fosamprenavir Versus Other Protease Inhibitors — Completed
• GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults — Completed
• A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. — Completed
• Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment — Completed
• A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) — Completed
• Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's — Completed
• A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine — Completed
• A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes — Completed
• Safety and Efficacy of Albiglutide in Type 2 Diabetes — Completed
• A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes — Completed
• Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes — Completed
• Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy — Completed
• Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures — Completed
• Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures — Completed
• ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. — Completed
• GSK BHR Study (Sont - Second Study) — Completed
• Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. — Completed
• A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) — Completed